• Simon Thompson, BohnMary KathrynMKPaediatric Laboratory Medicine, The Hospital for Sick Children, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Nicasio Mancini, Tze Ping Loh, Cheng-Bin Wang, Matthias Grimmler, Kwok-Yung Yuen, Robert Mueller, David Koch, Sunil Sethi, William D Rawlinson, Massimo Clementi, Rajiv Erasmus, Marc Leportier, Gye Cheol Kwon, María Elizabeth Menezes, Maria-Magdalena Patru, Maurizio Gramegna, Krishna Singh, Osama Najjar, Maurizio Ferrari, Giuseppe Lippi, Khosrow Adeli, Andrea R Horvath, and IFCC Taskforce on COVID-19.
• Department of Clinical Chemistry, NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW, Australia.
• Clin Chem Lab Med. 2020 Oct 7; 58 (12): 2009-2016.

AbstractRoutine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.

29 keywords...

hide…